Speakers

Associate Professor Kara Britt

Associate Professor Kara Britt leads the Breast Cancer Risk and Prevention Lab at Peter MacCallum Cancer Centre.

Kara obtained her PhD from Monash University working on female reproductive endocrinology. She then undertook a CJ Martin fellowship at the Institute of Cancer Research in the labs of Alan Ashworth and Matt Smalley moving to her passion of breast cancer research. Upon her return to Australia Kara also spent time under the mentorship of Gail Risbridger and Robin Anderson before beginning her own lab in 2016.

NZSO Kara Britt Photo

Prof. dr. Karin E. de Visser

Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam Professor Experimental Immunobiology of Cancer (specifically on the tumor microenvironment), Leiden University

Prof. dr. Karin E. de Visser obtained her PhD at the Division of Immunology at the Netherlands Cancer Institute in Amsterdam in the field of tumor immunotherapy. From 2003-2005 she worked as a postdoctoral fellow in the lab of Prof. dr. Lisa Coussens at the University of California, San Francisco, where she developed an active interest in the interplay between the adaptive and innate immune system during cancer development.

NZSO Karinde Visser resize

Bishal Gyawali

MD, PhD

Bishal Gyawali, MD, PhD is an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen’s University, Kingston, Canada . He is also an affiliated faculty at the Program on Regulation, Therapeutics and Law in the Department of Medicine at Brigham and Women's Hospital, Boston, USA. He is also a member of the WHO Essential Medicine List for Cancer Drugs, ESMO-Magnitude of Clinical Benefit Scale and ESMO-MCBS Quality of Life working groups. He is also currently serving as a research consultant to the Nepal Health Research Council and has previously served as a medical consultant for the not-for-profit Anticancer Fund, Belgium.

NZSO Bishal G 1

Dr. Mark A. Lewis

Dr. Mark A. Lewis received his medical degree, completed his internal medicine residency, and served as chief resident at Baylor College of Medicine in Houston, Texas. After completing a hematology/oncology fellowship at the Mayo Clinic in Rochester, Minnesota, where he served as chief fellow, he returned to Houston to work at the MD Anderson Cancer Center for four years, with a dual appointment in general & gastrointestinal medical oncology, before assuming the directorship of gastrointestinal oncology at Intermountain Healthcare in 2016.

NZSO Mark Lewis

Simione Lolohea

Simione Lolohea is a Colorectal Surgeon at Waikato and Braemar Hospital. He started at Waikato Hospital in 2005 after his 2 year Colorectal Fellowship Training. He is passionate about treatment of intra-peritoneal metastases.

He was instrumental in starting the Cytoreductive Surgery plus HIPEC treatment for Pseudomyxoma Peritonei and Colorectal Peritoneal Metastasis.

NZSO S Lolohea pic

Dr. Herbert H. Loong

MBBS, PDipMDPath, MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine)

Dr. Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team.

NZSO Herbert Loong WEB

Professor Diana Sarfati

(MBChB, MPH, PhD, FNZCPHM)

National Director of Cancer Control and Chief Executive of Te Aho o Te Kahu, the Cancer Control Agency in New Zealand.

Diana's role is to provide national leadership for, and oversight of cancer control, to provide policy advice to the Government, and to be accountable for ensuring progress towards the goals and outcomes in the New Zealand Cancer Action Plan.

NZSO Di photo resize

Professor David Snead

Professor Snead is a consultant cellular (anatomical) pathologist at the University Hospitals Coventry and Warwickshire NHS Trust (UHCW) and Professor of Pathology at the University of Warwick. He has been in post at Coventry for 25 years. He is the founding director of PathLAKE, one of five Innovate UK funded centres of excellence for the development of artificial intelligence in digital pathology and radiology.

NZSO David Snead

Dr Weigelt

Molecular Geneticist and Director of the Gynecology DMT Research Laboratory at Memorial Sloan Kettering Cancer Center

Dr Weigelt received her PhD from the Netherlands Cancer Institute, and undertook her postdoctoral training at Lawrence Berkeley National Laboratory, Berkeley, USA, and Cancer Research UK London Research Institute, London, UK, before moving to Memorial Sloan Kettering Cancer Center in New York, USA in 2012. Dr Weigelt is a Molecular Geneticist and the Director of the Gynecology DMT Research Laboratory at Memorial Sloan Kettering Cancer Center.

NZSO Weigelt B

Dr Michelle Wilson

Dr Michelle Wilson is a Staff Medical Oncologist at the Auckland City Hospital, and is the Clinical Director for Cancer and Blood Research at Auckland Hospital. She will be looking at how we challenge the paradigm of clinical trials and research across New Zealand.

NZSO Michelle Wilson photo

Dr Craig Underhill

Dr Craig Underhill is Director of Cancer Services at Albury-Wodonga Regional Cancer Centre; Clinical Director, Hume Regional Integrated Cancer Services and Regional Oncology Lead for the Victorian Comprehensive Cancer Centre (VCCC). He is conjoint senior lecturer at the University of NSW Clinical School in Albury. After training in Melbourne and working as a research fellow at Guys Hospital London and Ludwig Institute Melbourne Dr Underhill developed a medical oncology service in Albury-Wodonga, and established an independent not-for-profit Clinical Trials Unit (Border Medical Oncology Research Unit) which has twice been awarded NSW Premier's Award for Innovation in Cancer Clinical Trials.

NZSO Dr Craig Underhill pic test